CHICAGO ¨C Novo Nordisk¡¯s highly anticipated but ultimately unsuccessful Alzheimer¡¯s trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.
Novo¡¯s trials tested Rybelsus, an older pill form of semaglutide, the same main ingredient in Ozempic and Wegovy injections. The drug failed to meet the studies¡¯ primary goal of delaying cognitive decline in hundreds of people with early-stage Alzheimer¡¯s disease.
But in a release scant on details, the Danish drugmaker said Rybelsus did improve some unspecified Alzheimer¡¯s-related biological processes in both trials ¡ª clues that could help guide new studies, Alzheimer¡¯s experts said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.